Literature DB >> 28673046

Generation and characterization of a monoclonal antibody to the cytoplasmic tail of MUC16.

Ilene K Gipson1, Ulla Mandel2, Balaraj Menon1, Sandra Michaud1, Ann Tisdale1, Diana Campos3,4, Henrik Clausen2.   

Abstract

MUC16 is a large transmembrane mucin expressed on the apical surfaces of the epithelium covering the ocular surface, respiratory system and female reproductive tract. The transmembrane mucin is overexpressed by ovarian carcinomas, it is one of the most frequently used diagnostic markers for the disease and it is considered a promising target for immunotherapeutic intervention. Immunodetection of the mucin has to date been through antibodies that recognize its exceptionally large ectodomain. Similar to other membrane anchored mucins, MUC16 has a short cytoplasmic tail (CT), but studies of the biological relevance of the C-terminal domain of MUC16 has been limited by lack of availability of monoclonal antibodies that recognize the native CT. Here, we report the development of a novel monoclonal antibody to the CT region of the molecule that recognizes native MUC16 and its enzymatically released CT region. The antibody is useful for immunoprecipitation of the released CT domain as demonstrated with the OVCAR3 ovarian cancer cell line and can be used for detailed cytolocalization in cells as well as in frozen sections of ocular surface and uterine epithelium.
© The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CA125; MUC16 MAb; MUC16 cytoplasmic tail; transmembrane mucin

Mesh:

Substances:

Year:  2017        PMID: 28673046      PMCID: PMC6283312          DOI: 10.1093/glycob/cwx054

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  35 in total

1.  The CA 125 gene: an extracellular superstructure dominated by repeat sequences.

Authors:  T J O'Brien; J B Beard; L J Underwood; R A Dennis; A D Santin; L York
Journal:  Tumour Biol       Date:  2001 Nov-Dec

2.  Epitopes on CA 125 from cervical mucus and ascites fluid and characterization of six new antibodies. Third report from the ISOBM TD-1 workshop.

Authors:  K Nustad; Y Lebedin; K O Lloyd; K Shigemasa; H W A de Bruijn; B Jansson; O Nilsson; K H Olsen; T J O'Brien
Journal:  Tumour Biol       Date:  2002 Sep-Oct

3.  New monoclonal antibodies identify the glycoprotein carrying the CA 125 epitope.

Authors:  T J O'Brien; L M Raymond; G A Bannon; D H Ford; H Hardardottir; F C Miller; J G Quirk
Journal:  Am J Obstet Gynecol       Date:  1991-12       Impact factor: 8.661

4.  MUC16 is produced in tracheal surface epithelium and submucosal glands and is present in secretions from normal human airway and cultured bronchial epithelial cells.

Authors:  Julia R Davies; Sara Kirkham; Naila Svitacheva; David J Thornton; Ingemar Carlstedt
Journal:  Int J Biochem Cell Biol       Date:  2007-05-25       Impact factor: 5.085

5.  Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16.

Authors:  B W Yin; K O Lloyd
Journal:  J Biol Chem       Date:  2001-05-21       Impact factor: 5.157

6.  Assay of mucins in human tear fluid.

Authors:  Sandra Spurr-Michaud; Pablo Argüeso; Ilene Gipson
Journal:  Exp Eye Res       Date:  2007-02-07       Impact factor: 3.467

7.  Mucin gene expression in immortalized human corneal-limbal and conjunctival epithelial cell lines.

Authors:  Ilene K Gipson; Sandra Spurr-Michaud; Pablo Argüeso; Ann Tisdale; Tat Fong Ng; Cindy Leigh Russo
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-06       Impact factor: 4.799

8.  Interactions between MUC1 and p120 catenin regulate dynamic features of cell adhesion, motility, and metastasis.

Authors:  Xiang Liu; Chunhui Yi; Yunfei Wen; Prakash Radhakrishnan; Jarrod R Tremayne; Thongtan Dao; Keith R Johnson; Michael A Hollingsworth
Journal:  Cancer Res       Date:  2013-12-26       Impact factor: 12.701

9.  A metalloproteinase secreted by Streptococcus pneumoniae removes membrane mucin MUC16 from the epithelial glycocalyx barrier.

Authors:  Bharathi Govindarajan; Balaraj B Menon; Sandra Spurr-Michaud; Komal Rastogi; Michael S Gilmore; Pablo Argüeso; Ilene K Gipson
Journal:  PLoS One       Date:  2012-03-07       Impact factor: 3.240

10.  Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.

Authors:  Thapi D Rao; Huasong Tian; Xun Ma; Xiujun Yan; Sahityasri Thapi; Nikolaus Schultz; Nestor Rosales; Sebastien Monette; Amy Wang; David M Hyman; Douglas A Levine; David Solit; David R Spriggs
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

View more
  1 in total

Review 1.  MUC16 as a novel target for cancer therapy.

Authors:  Abhijit Aithal; Sanchita Rauth; Prakash Kshirsagar; Ashu Shah; Imayavaramban Lakshmanan; Wade M Junker; Maneesh Jain; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Expert Opin Ther Targets       Date:  2018-07-26       Impact factor: 6.902

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.